GTHX - G1 Therapeutics

-

$undefined

N/A

(N/A)

G1 Therapeutics NASDAQ:GTHX G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C.

Location: 700 Park Offices Drive, Suite 200, North Carolina, 27709, US | Website: www.g1therapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

364.5M

Cash

60.73M

Avg Qtr Burn

-9.385M

Short % of Float

8.71%

Insider Ownership

10.92%

Institutional Own.

54.62%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
COSELA™ Trilaciclib (G1T28) (CDK4/6 inhibitor) Details
Cancer, Solid tumor/s, Small cell lung cancer

Approved

Quarterly sales

Trilaciclib (Cosela) (CDK4/6 inhibitor) Details
Breast cancer, Cancer, Triple-negative breast cancer

Phase 3

Update

Phase 2

Update

Trilaciclib (Cosela) + Trodelvy® (sacituzumab govitecan-hziy) (ADC) Details
Solid tumor/s, Cancer, Metastatic breast cancer, Triple-negative breast cancer , Breast cancer

Phase 2

Update

Phase 2

Update

Failed

Discontinued

Trilaciclib (Cosela) (CDK4/6 inhibitor) Details
Cancer, Non-small cell lung carcinoma, Solid tumor/s

Failed

Discontinued

Failed

Discontinued